Clinical Trials
62 trialsNCT03937830 2026-06-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05211323 2026-06-03
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT04196465 2026-05-22
NeoChance
Asan Medical Center
Phase 2 Active not recruiting
NCT06084884 2026-05-22
ATHENA
AstraZeneca
Phase 1/2 Active not recruiting
NCT02984566 2026-05-19
TROG1703 LARK
University of Sydney
Phase NA Active not recruiting
NCT06904365 2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
NCT03143270 2026-05-07
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05883644 2026-04-30
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT04145141 2026-04-21
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT02954094 2026-04-17
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Target PharmaSolutions, Inc.
Active not recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT02381561 2026-04-13
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT03408665 2026-03-30
STEREOLIVER
Centre Oscar Lambret
Phase NA Active not recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05128032 2026-03-19
PEDIR
Massachusetts General Hospital
Phase NA Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05743842 2026-03-09
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05953337 2026-03-04
Radioembolization Trial Utilizing Eye90 Microspheresâ„¢ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
Phase NA Active not recruiting
NCT05438420 2026-02-24
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Active not recruiting
NCT04258813 2026-02-20
ONE TEAM
Duke University
Phase NA Active not recruiting
NCT04736121 2026-02-03
DOORwaY90
Sirtex Medical
Phase NA Active not recruiting
NCT07362264 2026-01-23
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Active not recruiting
NCT04377932 2026-01-21
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT00582647 2026-01-15
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04573881 2026-01-12
#HOPE4LIVER
HistoSonics, Inc.
Phase NA Active not recruiting
NCT01494324 2026-01-02
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03623464 2025-12-17
RCT of Mobile Apps & FitBit v. Usual Care
Weill Medical College of Cornell University
Phase NA Active not recruiting
NCT02869217 2025-12-03
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
Phase 1 Active not recruiting
NCT03383458 2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04572633 2025-11-19
#HOPE4LIVER US
HistoSonics, Inc.
Phase NA Active not recruiting
NCT06141564 2025-11-18
DTECT-Liver
Johns Hopkins University
Active not recruiting
NCT07233759 2025-11-18
The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.
National Taiwan University Hospital
Active not recruiting
NCT05064553 2025-10-15
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
Active not recruiting
NCT07214363 2025-10-09
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
National Taiwan University Hospital
Phase NA Active not recruiting
NCT07207343 2025-10-03
Symptomatic Abdominal Tumors Are Unsuitable for Surgical Resection, High-intensity Focused Ultrasound (HIFU) Treatment Will be Applied to the Tumors. Postoperatively, Continuous Evaluation and Analysis of the Ablation Effect Will be Performed Using CT or MRI Imaging.
National Taiwan University Hospital
Phase NA Active not recruiting
NCT03993873 2025-10-01
SHIELD-1
Turning Point Therapeutics, Inc.
Phase 1 Active not recruiting
NCT02932956 2025-09-19
GAP
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07034950 2025-09-11
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation
The First Affiliated Hospital of Xiamen University
Phase 1/2 Active not recruiting
NCT03132792 2025-08-15
AFPᶜ³³²T in Advanced HCC
Adaptimmune
Phase 1 Active not recruiting
NCT06384417 2025-08-08
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
Phase NA Active not recruiting
NCT03651154 2025-07-31
PRICE2
Ottawa Hospital Research Institute
Phase NA Active not recruiting